Quibim, a company developing imaging biomarkers for precision medicine that has created AI-based software to identify early-stage neurodegenerative diseases, has announced the launch of QP-Brain.
This follows the product receiving an FDA 510(k) clearance from the US Food and Drug Administration, a CE mark for the EU and a UKCA mark for the UK.
The product is now cleared to be used by clinicians in all the above markets.
Currently, the vast majority of neurological disease detection comes from qualitative analysis from radiologists and neurologists.
This solely human-based approach means that neurological are often only detected in their later stages.
To solve this issue, healthcare institutions require advanced and versatile quantitative AI-based tools that can also provide secure, transfer and storage of patients’ data and augment the workflow of clinicians.
Quibim designed QP-Brain to facilitate quantitative analysis of patients’ brains by using an AI-based tool that automatically quantifies and displays results based on the data from MRI Scans directly in PACS.
The technology measures brain regions to detect subtle alterations, providing quantitative information to healthcare professionals , optimising the process of radiological reporting.
The technology also provides quantification and visualisation of imaging findings which is useful for identifying patterns of brain atrophy and neurodegenerative diseases like Alzheimer’s, MS and vascular and frontotemporal dementia, at earlier stages.
The technology also makes reporting more effective and offers hospitals a secure way of processing and analysing patient data and can be easily installed on a hospital server behind firewalls through a secure cloud architecture.
Dr Angel Alberich Bayarri, Quibim’s founder and CEO, said: “Receiving regulatory clearance for QP-Brain in the US, EU and UK is a huge milestone for Quibim and for the early-stage detection of neurological diseases.
“At Quibim our mission is to develop AI technology that augments the essential role played by human medical experts to improve patient outcomes, by detecting neurological diseases and cancers much earlier than is currently possible.”
